The management of
lung cancer has changed considerably in recent times. There are
refinements in the pathological classification and staging of lung cancer
allowing better individualisation of treatment. With the development
of targeted therapies for advanced or metastatic lung cancer in addition to conventional
treatments, a new paradigm of personalising lung cancer treatment has
emerged. This is changing clinical practice with clinicians needing to be
aware of new therapeutic options and understanding the implications of
co-dependent technologies. Indeed the continued and rapid discovery
of novel targets for treatments lead to the challenge of how to optimally
transfer research to practice. This talk will focus on the major changes
in lung cancer treatment in the molecular era.